Millions of people in the U.S. have sleep apnea, most of whom aren’t getting treated for it. But a simple daily pill of an old drug just might help people with the condition, recent trial data shows.

A European clinical trial found that the drug sulthiame significantly reduced breathing interruptions in people with moderate to severe sleep apnea. Patients taking higher doses experienced up to 47% ...

Sleep apnea sufferers may soon have a new path to a good night’s sleep. A Massachusetts biotech startup is preparing to file for FDA approval of a once-nightly pill that could become the first ...

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage ...

The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea ...

A new drug appears to reverse the fuzzy thinking caused by a lack of sleep. Studies in monkeys and people show that the drug restores the ability to perform complex mental tasks. The research is being ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. The Massachusetts biotech reported May 19 that AD109 met the primary endpoint of a phase 3 trial, reducing ...

Zepbound, a drug that rivals Ozempic, may one day be a treatment for sleep apnea, according to results from a new study. Jessica was a writer on the Wellness team, with a focus on health technology, ...

Weight loss pills and injections are often touted as miracle drugs. Research shows that they can help you lose weight, better help you manage type II diabetes, and even reduce your risk of heart ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

The disease affects as many as 80 million in the U.S. alone. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval. In November 2016, ...